Chiron has reported encouraging preliminary results from a pivotaltrial of TFPI (tissue factor pathway inhibitor) in sepsis, raising expectations that the drug may prove successful in this notoriously recalcitrant indication. The drug is being co-developed with Pharmacia, and the ongoing Phase III program could generate results in late 2001 or early 2002, according to analysts at Deutsche Banc Alex Brown, who have upgraded the firm to strong buy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze